BMO Capital Markets Has Lowered Expectations for Medpace (NASDAQ:MEDP) Stock Price

Medpace (NASDAQ:MEDP) had its target price cut by equities researchers at BMO Capital Markets from $460.00 to $400.00 in a report released on Friday,Benzinga reports. The firm presently has a “market perform” rating on the stock. BMO Capital Markets’ target price points to a potential downside of 1.29% from the company’s previous close.

Several other analysts also recently commented on the company. Barclays set a $450.00 price objective on Medpace in a research note on Friday. Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Truist Financial dropped their price objective on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research note on Wednesday, February 11th. Zacks Research downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Finally, Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Four investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $467.08.

Medpace Price Performance

Shares of MEDP stock traded up $11.82 during trading hours on Friday, reaching $405.24. The company had a trading volume of 131,558 shares, compared to its average volume of 357,527. The company has a 50 day moving average of $470.96 and a 200 day moving average of $536.55. The firm has a market cap of $11.57 billion, a price-to-earnings ratio of 25.37, a P/E/G ratio of 2.39 and a beta of 1.39. Medpace has a 1-year low of $284.10 and a 1-year high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. Medpace had a return on equity of 149.31% and a net margin of 17.19%.The firm’s quarterly revenue was up 26.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts forecast that Medpace will post 17.05 EPS for the current fiscal year.

Insider Buying and Selling at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president owned 15,000 shares in the company, valued at $6,829,500. This trade represents a 67.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 20.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Medpace

Several hedge funds have recently modified their holdings of the stock. Fifth Third Wealth Advisors LLC grew its holdings in shares of Medpace by 2.6% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock valued at $379,000 after acquiring an additional 19 shares in the last quarter. BOKF NA grew its holdings in shares of Medpace by 0.8% in the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after acquiring an additional 20 shares in the last quarter. Valeo Financial Advisors LLC grew its holdings in shares of Medpace by 5.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock valued at $249,000 after acquiring an additional 21 shares in the last quarter. HighPoint Advisor Group LLC grew its holdings in shares of Medpace by 2.8% in the 3rd quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock valued at $416,000 after acquiring an additional 22 shares in the last quarter. Finally, UMB Bank n.a. grew its holdings in shares of Medpace by 5.6% in the 4th quarter. UMB Bank n.a. now owns 450 shares of the company’s stock valued at $253,000 after acquiring an additional 24 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Q1 results beat expectations: GAAP EPS of $4.28 topped consensus and revenue of $706.6M beat estimates, with revenue up ~26.5% YoY — showing strong near-term profitability and margin performance. Medpace (MEDP) Q1 Earnings and Revenues Beat Estimates
• Positive Sentiment: Backlog still sizeable (~$2.93B at quarter-end), which supports multi‑quarter revenue visibility even as bookings fluctuate. Medpace Holdings, Inc. Reports First Quarter 2026 Results
• Neutral Sentiment: Company maintained FY2026 guidance (EPS range $16.68–$17.50; revenue ~$2.8–$2.9B) — roughly in line with consensus on revenue but the EPS range sits near/below some street estimates, leaving mixed signals. Medpace Q1 Press Release / Guidance
• Neutral Sentiment: Robert W. Baird lowered its price target from $565 to $477 but retained an “Outperform” rating — a signal that some analysts are trimming near-term upside while remaining constructive longer term. Baird Lowers Price Target
• Negative Sentiment: Bookings weakness: net new business awards were $618.4M producing a book‑to‑bill of ~0.88x (below 1.0), raising concerns about demand/near‑term revenue sustainability and prompting the market selloff. Medpace slides as Q1 book-to-bill drops below 1
• Negative Sentiment: Leadership and legal risk: the company disclosed President Jesse Geiger’s impending retirement (CEO to reassume president duties temporarily), and multiple law firms have filed or are soliciting lead plaintiffs in securities class actions — increasing uncertainty and potential litigation costs. Class action notice / investigations

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.